Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats

Author(s):  Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E

Issue:  May/Jun 2017 - Volume 21, Number 3
View All Articles in Issue

Page(s):  242-246

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 1
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 2
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 3
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 4
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 5

Download in electronic PDF format for $75

Abstract:  The objective of this study was to compare serum concentrations of transdermal fluoxetine compounded in Lipoderm base versus commercially available oral fluoxetine tablets. Sixteen clinically healthy, client-owned cats that were at least one year of age were enrolled. Cats weighed between three and seven kilograms, had no comorbidities, and were behavior medication naïve. Cats were recruited from January 2016 through April 2016. Eight cats were assigned to each medication group based on owner preference. The cats received either oral (1 mg/kg) or transdermal (5 mg/kg; maximum 25 mg daily) fluoxetine compounded in a transdermal base (PCCA Lipoderm), administered daily for 60 days. Serum levels of fluoxetine and norfluoxetine were assessed as a surrogate for relative efficacy. Serum was collected and analyzed by high-performance liquid chromatography-mass spectrometry/mass spectrometry at baseline and days 5, 10, 30, 45, and 60 post-drug start. Adverse effects were monitored during physical exams, speaking with owners, and laboratory analysis of liver function tests at baseline and days 5, 30, and 60 post-drug start. Serum fluoxetine concentrations significantly differed between the treatment groups at days 45 and 60 post-drug start. Norfluoxetine concentrations significantly differed at days 30, 45, and 60 post-drug start. Blood concentrations of fluoxetine and norfluoxetine significantly differed between oral and transdermal routes after 30 days of treatment. Oral fluoxetine concentrations were consistently higher. Transdermal fluoxetine appeared to be well-tolerated, but a lack of knowledge regarding effective blood levels makes it unclear if a clinical effective response would be obtained at the blood concentrations achieved.

Related Keywords: fluoxetine, selective serotonin reuptake inhibitor, SSRI, felines, anxiety, behavioral disorders, obsessive compulsive disorder, OCD, topical preparation, transdermal administration, transdermal absorption, serum drug concentrations, oral preparation, dosage form comparison

Related Categories: PEER-REVIEWED, VETERINARY, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats
Eichstadt Lauren R
, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E
May/Jun 2017
Pg. 242-246

Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety
Fields Shannon W
Nov/Dec 2006
Pg. 418

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
Sep/Oct 2018
Pg. 409

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Fluoxetine Hydrochloride 1-mg/mL Oral Liquid
Allen Loyd V Jr
Jan/Feb 2007
Pg. 73

Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F
, Sauvageot Jurgita
May/Jun 2014
Pg. 253-255

Unlicensed Transdermal Medications in Feline Patients: Three Case Reports
Urwin Craig
, Jean Linda, Carvalho Maria, Robson-Laws Michael
Nov/Dec 2022
Pg. 468-472

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases
Mixon William
, Helms Scott R
Sep/Oct 2008
Pg. 392-397

Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48

Psychotropic Medications in the Treatment of Feline Urine Spraying
Simpson Barbara Sherman
, Vail Jane
Jan/Feb 2007
Pg. 44-48

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Extemporaneous Preparation of Sertraline Cream for Transdermal Administration
Wynn Tom
, Goetsch Daniel
May/Jun 2011
Pg. 200-203

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Compounding Pearls -- Wound Care: Base Selection
Riepl Mike
Mar/Apr 2020
Pg. 98-102

Compounding Transdermal Medication for Feline Patients
Eichstadt Lauren R
Jul/Aug 2016
Pg. 271-274

Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Riepl Mike
, Kaiser Joe
Sep/Oct 2023
Pg. 368-380

Feline Transdermal Formulation Considerations
Forsythe Lauren Eichstadt
Nov/Dec 2017
Pg. 446-452

Return to Top